Agios Pharmaceuticals.
a public American pharmaceutical company
- Reports this week
- 0
- Active events
- 1
- Connections
- 47
What's happening
Active this week
One to three months ago
-
Manufacturers Life Insurance Company reduced its stake in Agios Pharmaceuticals and filed the transaction with the SEC.Some support1 report
-
Direct market comparison of financial health between Agios Pharmaceuticals and DT Cloud Star Acquisition Corp.Some support1 report
-
Bank of America, Royal Bank of Canada, and Truist Financial raised price targets for Agios Pharmaceuticals on July 31, 2026.Some support2 reports
-
Agios Pharmaceuticals is seeking regulatory approval for its drug candidates from the FDA.Some support1 report
-
Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.Well supported3 reports
Gone quiet
No new reports in 90+ days-
The FDA is reviewing the label expansion application for Pyrukynd, a drug involving Agios Pharmaceuticals and Phathom Pharmaceuticals, Inc.Some support1 report
-
Agios Pharmaceuticals, located in Cambridge, Mass., has identified its corporate structure and key personnel.Some support2 reports
-
FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.Some support1 report
-
Agios Pharmaceuticals is preparing for potential product launches in Europe and the Gulf region, including Saudi Arabia and the UAE.Some support1 report
-
FDA extended PDUFA goal date for PYRUKYND and Agios submitted REMS to mitigate hepatocellular injury risk.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Agios Pharmaceuticals this week
News at the entities that move Agios Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Agios Pharmaceuticals
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Agios Pharmaceuticals
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Agios Pharmaceuticals
-
Truist Financial TransactionalMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Agios Pharmaceuticals
-
Manufacturers Life Insurance Company TransactionalManufacturers Life Insurance Company purchased a new stake in Telos shares, a company serving customers in the United States.Moves Agios Pharmaceuticals
-
DoorDash OperationalDoorDash paid NYC workers $131.5 million, and Gavin Newsom signed a partnership with Finland.Moves Agios Pharmaceuticals
Connections
The 12 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Agios Pharmaceuticals, overseeing drug approvals, label expansions, and adverse event reporting.
-
Sarah Gheuens Structural
Sarah Gheuens serves as Chief Medical Officer and Head of R&D at Agios Pharmaceuticals.
-
Securities and Exchange Commission Structural
Agios Pharmaceuticals operates under the regulatory oversight and reporting requirements of the SEC.
-
SEC Structural
Agios Pharmaceuticals is subject to regulatory oversight by the SEC, requiring the filing of disclosures.
-
Truist Financial Transactional
Truist Financial raised its price target on Agios Pharmaceuticals stock.
-
Manufacturers Life Insurance Company Transactional
Manufacturers Life Insurance Company reduced its ownership stake in Agios Pharmaceuticals.
-
TipRanks Mentioned together
The entities are co-mentioned in the context of market coverage tracked via financial services.
-
Cambridge Shared context
Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts.
Show all 12 connections
-
Novo Nordisk Operational
The two companies are direct competitors regarding the oral pyruvate kinase-R activator market.
-
DoorDash Operational
The relationship is labeled as competitive, suggesting ongoing market interaction between the two companies.
-
Bank of America Mentioned together
Bank of America provided an analyst rating update on Agios Pharmaceuticals' stock.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada raised a price target on the stock of Agios Pharmaceuticals.
History
Events by the month they beganAugust 2026
2 eventsJuly 2026
3 events- Bank of America, Royal Bank of Canada, and Truist Financial raised price targets for Agios Pharmaceuticals on July 31, 2026.
- Agios Pharmaceuticals is seeking regulatory approval for its drug candidates from the FDA.
- Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
June 2026
6 events- Trump's pledge to unleash oil and gas benefits certain stocks.
- The FDA is reviewing the label expansion application for Pyrukynd, a drug involving Agios Pharmaceuticals and Phathom Pharmaceuticals, Inc.
- Agios Pharmaceuticals, located in Cambridge, Mass., has identified its corporate structure and key personnel.
- FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.
- Agios Pharmaceuticals is preparing for potential product launches in Europe and the Gulf region, including Saudi Arabia and the UAE.
- FDA extended PDUFA goal date for PYRUKYND and Agios submitted REMS to mitigate hepatocellular injury risk.